Single User License
INR 100335
Site License
INR 200670
Corporate User License
INR 301005

Service Tax Additional

select a format

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

Actavis plc-Product Pipeline Review-2015

Actavis plc-Product Pipeline Review-2015

  Request for Sample Report

Executive Summary

Actavis plc-Product Pipeline Review-2015


Global Markets Direct's, 'Actavis plc-Product Pipeline Review-2015', provides an overview of the Actavis plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Actavis plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Actavis plc including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Actavis plc's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Actavis plc's pipeline products

Reasons To Buy

Evaluate Actavis plc's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Actavis plc in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Actavis plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Actavis plc and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Actavis plc

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Actavis plc and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Actavis plc Snapshot 7

Actavis plc Overview 7

Key Information 7

Key Facts 7

Actavis plc-Research and Development Overview 8

Key Therapeutic Areas 8

Actavis plc-Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products-Monotherapy 13

Pipeline Products-Combination Treatment Modalities 14

Pipeline Products-Partnered Products 15

Partnered Products/Combination Treatment Modalities 16

Actavis plc-Pipeline Products Glance 17

Actavis plc-Late Stage Pipeline Products 17

Pre-Registration Products/Combination Treatment Modalities 17

Filing rejected/Withdrawn Products/Combination Treatment Modalities 18

Phase III Products/Combination Treatment Modalities 19

Actavis plc-Clinical Stage Pipeline Products 20

Phase II Products/Combination Treatment Modalities 20

Phase I Products/Combination Treatment Modalities 21

Actavis plc-Early Stage Pipeline Products 22

IND/CTA Filed Products/Combination Treatment Modalities 22

Discovery Products/Combination Treatment Modalities 23

Actavis plc-Drug Profiles 24

APT-1026 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

cariprazine 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

norethindrone 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

(aclidinium bromide + formoterol fumarate) 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

(ceftazidime + avibactam sodium) 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

bimatoprost 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

cyclosporine 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

dalbavancin 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

follitropin alfa (recombinant) 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

onabotulinumtoxin A 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

pancrelipase DR 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

sarecycline hydrochloride 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

udenafil 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

ulipristal acetate 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

WC-3011 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

(ceftaroline fosamil + avibactam sodium) 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

memantine hydrochloride 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

oxybutynin chloride 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

EUR-1100 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

AGN-232411 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Progesterone Second Generation 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

bezafibrate ER 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Actavis plc-Pipeline Analysis 57

Actavis plc-Pipeline Products by Target 57

Actavis plc-Pipeline Products by Route of Administration 59

Actavis plc-Pipeline Products by Molecule Type 60

Actavis plc-Pipeline Products by Mechanism of Action 61

Actavis plc-Recent Pipeline Updates 63

Actavis plc-Dormant Projects 83

Actavis plc-Discontinued Pipeline Products 85

Discontinued Pipeline Product Profiles 85

alvameline maleate 85

dexamethasone 85

dexloxiglumide 85

ME-1036 85

neramexane mesylate 86

oglemilast 86

onabotulinumtoxin A 86

radiprodil 86

Actavis plc-Company Statement 87

Actavis plc-Locations And Subsidiaries 92

Head Office 92

Other Locations & Subsidiaries 92

Appendix 100

Methodology 100

Coverage 100

Secondary Research 100

Primary Research 100

Expert Panel Validation 100

Contact Us 100

Disclaimer 101

List of Tables

Actavis plc, Key Information 7

Actavis plc, Key Facts 7

Actavis plc-Pipeline by Indication, 2015 10

Actavis plc-Pipeline by Stage of Development, 2015 12

Actavis plc-Monotherapy Products in Pipeline, 2015 13

Actavis plc-Combination Treatment Modalities in Pipeline, 2015 14

Actavis plc-Partnered Products in Pipeline, 2015 15

Actavis plc-Partnered Products/ Combination Treatment Modalities, 2015 16

Actavis plc-Pre-Registration, 2015 17

Actavis plc-Filing rejected/Withdrawn, 2015 18

Actavis plc-Phase III, 2015 19

Actavis plc-Phase II, 2015 20

Actavis plc-Phase I, 2015 21

Actavis plc-IND/CTA Filed, 2015 22

Actavis plc-Discovery, 2015 23

Actavis plc-Pipeline by Target, 2015 57

Actavis plc-Pipeline by Route of Administration, 2015 59

Actavis plc-Pipeline by Molecule Type, 2015 60

Actavis plc-Pipeline Products by Mechanism of Action, 2015 61

Actavis plc-Recent Pipeline Updates, 2015 63

Actavis plc-Dormant Developmental Projects,2015 83

Actavis plc-Discontinued Pipeline Products, 2015 85

Actavis plc, Subsidiaries 92

List of Figures

Actavis plc-Pipeline by Top 10 Indication, 2015 9

Actavis plc-Pipeline by Stage of Development, 2015 12

Actavis plc-Monotherapy Products in Pipeline, 2015 13

Actavis plc-Combination Treatment Modalities in Pipeline, 2015 14

Actavis plc-Partnered Products in Pipeline, 2015 15

Actavis plc-Pipeline by Top 10 Target, 2015 57

Actavis plc-Pipeline by Top 10 Route of Administration, 2015 59

Actavis plc-Pipeline by Top 10 Molecule Type, 2015 60

Actavis plc-Pipeline Products by Top 10 Mechanism of Action, 2015 61

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of Actavis plc; Actavis plc - Key Therapeutics; Actavis plc - Pipeline Overview and Promising Molecules; Actavis plc - News; Actavis plc - Latest Updates; Actavis plc - Pipeline; Actavis plc - Discontinued/Dormant Projects

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]